Evidence map›Paper›PMID 37072836›Full record

ReviewBiomaterials research2023

Progress and emerging techniques for biomaterial-based derivation of mesenchymal stem cells (MSCs) from pluripotent stem cells (PSCs).

Nityanand Prakash, Jiseong Kim, Jieun Jeon, Siyeon Kim, Yoshie Arai, Alvin Bacero Bello, Hansoo Park, Soo-Hong Lee

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomaterials research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Current advancements in nanotechnology for stem cells.International journal of surgery (London, England) · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nityanand PrakashDepartment of Biomedical Engineering, Dongguk University, Seoul, 04620, Korea.
Jiseong KimDepartment of Biomedical Engineering, Dongguk University, Seoul, 04620, Korea.
Jieun JeonDepartment of Biomedical Engineering, Dongguk University, Seoul, 04620, Korea.
Siyeon KimDepartment of Biomedical Engineering, Dongguk University, Seoul, 04620, Korea.
Yoshie AraiDepartment of Biomedical Engineering, Dongguk University, Seoul, 04620, Korea.
Alvin Bacero BelloDepartment of Biomedical Engineering, Dongguk University, Seoul, 04620, Korea. abacerobello@gmail.com.
Hansoo ParkSchool of Integrative Engineering, Chung-Ang University, Seoul, 06911, Korea. heyshoo@cau.ac.kr.
Soo-Hong LeeDepartment of Biomedical Engineering, Dongguk University, Seoul, 04620, Korea. soohong@dongguk.edu.
Dongguk University · KRChung-Ang University · KR

Funding

Ministry of Science and ICT, South Korea NRF-2019M3A9H1032376Ministry of Science and ICT, South Korea NRF-2022R1A2C3004850
6 · The paper itself

Abstract

The use of mesenchymal stem cells (MSCs) for clinical purposes has skyrocketed in the past decade. Their multilineage differentiation potentials and immunomodulatory properties have facilitated the discovery of therapies for various illnesses. MSCs can be isolated from infant and adult tissue sources, which means they are easily available. However, this raises concerns because of the heterogeneity among the various MSC sources, which limits their effective use. Variabilities arise from donor- and tissue-specific differences, such as age, sex, and tissue source. Moreover, adult-sourced MSCs have limited proliferation potentials, which hinders their long-term therapeutic efficacy. These limitations of adult MSCs have prompted researchers to develop a new method for generating MSCs. Pluripotent stem cells (PSCs), such as embryonic stem cells and induced PSCs (iPSCs), can differentiate into various types of cells. Herein, a thorough review of the characteristics, functions, and clinical importance of MSCs is presented. The existing sources of MSCs, including adult- and infant-based sources, are compared. The most recent techniques for deriving MSCs from iPSCs, with a focus on biomaterial-assisted methods in both two- and three-dimensional culture systems, are listed and elaborated. Finally, several opportunities to develop improved methods for efficiently producing MSCs with the aim of advancing their various clinical applications are described.

Indexed as

BiomaterialInduced pluripotent stem cell (iPSC)iPSC-derived MSCMesenchymal stem cell (MSC)MSC derivation

Identifiers

PMID37072836
PMCPMC10114339
OpenAlexW4366272836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.